The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force behind this resurgence.

Questex’s Fierce Biotech today announces the winners of the 2026 Fierce Outsourcing Awards, recognizing the companies and teams driving innovation, performance, and partnership across the outsourced ...

Eli Lilly, the maker of the popular GLP-1 injectable Mounjaro, has invested heavily in Houston as a biotechnology hub.

NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural ...

For decades, venture capitalists have relied on a tried-and-true recipe to make money in biotech. Now that approach is being ...

Collaboration leverages Converge Bio's proprietary generative AI to design and optimize novel tri-specific antibodies for oncology needs AI-driven development strategy designed to significantly ...

According to market consultancy Frost & Sullivan, the global AI-enabled pharmaceutical R&D market is projected to grow from ...

Scientists are raising a provocative hypothesis about GLP-1 drugs for obesity: Perhaps targeting the GLP-1 hormone isn't ...

The University of Hong Kong (HKU) and Grand Pharmaceutical Group Limited (Grand Pharmaceutical) have officially signed a research collaboration agreement, marking a significant step toward integrating ...

Biotech has long been one of the strongest sector stories of the past year, and investors who got there early have been rewarded. As of April 2, 2026, the State Street SPDR S&P Biotech ETF (NYSE:XBI) ...

Gossamer Bio is picking up the pieces after failing to bring its only late-stage drug to market. The local biotech plans to lay off 65 San Diegans, almost half of its total workforce. While the ...